Experimental Alzheimer’s drug may have contributed to death of study participant, according to reports
By Jen Christensen, CNN A monoclonal antibody treatment for Alzheimer’s disease that showed promise in a Phase 3 trial may have contributed to a study participant’s death, according to an adverse events report obtained by the digital health publication Stat. Eisai, the company that makes the experimental drug lecanemab, said in a statement to CNN
Continue Reading